ING Groep NV Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX

ING Groep NV bought a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in the 3rd quarter, Holdings Channel reports. The institutional investor bought 11,989 shares of the pharmaceutical company’s stock, valued at approximately $4,695,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Madison Asset Management LLC raised its position in Vertex Pharmaceuticals by 14.2% during the third quarter. Madison Asset Management LLC now owns 16,201 shares of the pharmaceutical company’s stock valued at $6,345,000 after purchasing an additional 2,009 shares in the last quarter. Advisors Asset Management Inc. boosted its holdings in shares of Vertex Pharmaceuticals by 3.4% in the 3rd quarter. Advisors Asset Management Inc. now owns 25,926 shares of the pharmaceutical company’s stock valued at $10,154,000 after purchasing an additional 841 shares in the last quarter. BridgePort Financial Solutions LLC increased its stake in shares of Vertex Pharmaceuticals by 17.6% in the 3rd quarter. BridgePort Financial Solutions LLC now owns 991 shares of the pharmaceutical company’s stock valued at $388,000 after purchasing an additional 148 shares during the last quarter. Midwest Trust Co raised its holdings in shares of Vertex Pharmaceuticals by 8.6% during the 3rd quarter. Midwest Trust Co now owns 620 shares of the pharmaceutical company’s stock worth $243,000 after buying an additional 49 shares in the last quarter. Finally, Linden Thomas Advisory Services LLC raised its holdings in shares of Vertex Pharmaceuticals by 3.2% during the 3rd quarter. Linden Thomas Advisory Services LLC now owns 8,419 shares of the pharmaceutical company’s stock worth $3,297,000 after buying an additional 258 shares in the last quarter. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ VRTX opened at $465.02 on Friday. The company has a 50 day simple moving average of $459.26 and a 200 day simple moving average of $427.55. Vertex Pharmaceuticals Incorporated has a 1 year low of $362.50 and a 1 year high of $519.68. The firm has a market cap of $117.98 billion, a PE ratio of 32.79 and a beta of 0.30.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share for the quarter, missing analysts’ consensus estimates of $5.05 by ($0.02). The business had revenue of $3.19 billion for the quarter, compared to the consensus estimate of $3.18 billion. Vertex Pharmaceuticals had a return on equity of 23.51% and a net margin of 31.35%.The company’s revenue was up 9.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.98 earnings per share. As a group, research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Vertex Pharmaceuticals news, EVP Edward Morrow Atkinson III sold 1,751 shares of the company’s stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $460.43, for a total value of $806,212.93. Following the sale, the executive vice president owned 22,046 shares in the company, valued at approximately $10,150,639.78. The trade was a 7.36% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Ourania Tatsis sold 466 shares of the firm’s stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $460.43, for a total value of $214,560.38. Following the transaction, the executive vice president owned 51,436 shares of the company’s stock, valued at $23,682,677.48. This trade represents a 0.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 99,352 shares of company stock valued at $45,037,314 over the last ninety days. 0.20% of the stock is currently owned by corporate insiders.

Vertex Pharmaceuticals News Summary

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Revenue and product momentum: Vertex reported quarter-over-quarter revenue growth (total revenue ~$3.19B, ~+9.5% YoY), which some outlets framed as a revenue beat or in-line with estimates — supporting confidence in core cystic fibrosis franchises. Vertex Q4 Revenue Beats
• Positive Sentiment: Pipeline expansion: Vertex announced a partnership with WuXi to broaden its autoimmune pipeline beyond cystic fibrosis, which could diversify future revenue streams and reduce single-therapy concentration risk. Partnership with WuXi
• Neutral Sentiment: 2026 guidance broadly in-line: Management gave revenue guidance centered around ~$13.0–13.1B, which Reuters and the company describe as roughly matching analysts’ expectations; this limits downside from guidance but doesn’t materially raise the bar. Reuters: Guidance In-Line
• Neutral Sentiment: Analyst sentiment and valuation context: Multiple analysts maintain bullish ratings and above-consensus price targets (median targets well above current levels), supporting longer-term upside; valuation and momentum write-ups are circulating for investors weighing entry timing. Zacks: Momentum Thesis
• Negative Sentiment: Small EPS miss and mixed beats: EPS came in marginally below consensus (reported ~$5.03 vs. estimates near $5.05–$5.07), and some data feeds showed revenue slightly under certain Street models — a near-term driver for the post-release price pullback among short-term traders. Zacks: EPS Miss Zacks: Metric Comparison
• Negative Sentiment: Insider selling: Multiple senior executives disclosed stock sales (several EVPs and the CAO among them), and trackers note a pattern of insider liquidations over recent months — this raises short-term sentiment risk even if sales are routine diversification. Quiver: Insider Selling and Earnings Reaction

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on VRTX shares. Leerink Partners raised their price objective on Vertex Pharmaceuticals from $456.00 to $525.00 and gave the company an “outperform” rating in a research note on Monday, December 29th. Stifel Nicolaus reduced their price target on shares of Vertex Pharmaceuticals from $455.00 to $445.00 and set a “hold” rating on the stock in a research note on Tuesday, November 4th. Barclays raised shares of Vertex Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $414.00 to $606.00 in a report on Tuesday, January 27th. Scotiabank started coverage on shares of Vertex Pharmaceuticals in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $495.00 price objective for the company. Finally, Wolfe Research raised shares of Vertex Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $548.00 target price on the stock in a research note on Tuesday, January 6th. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $522.68.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.